Decheng backs Nanjing Bioheng in series A

Nanjing Bioheng Biotech Co., Ltd. (Nanjing, China) raised RMB100 million ($14.8 million) in a series A round financing. Decheng Capital was the sole investor.

Founded in 2017, Nanjing Bioheng is developing immunotherapies and next-generation gene therapies for cancer and other diseases. Its pipeline includes six off-the-shelf allogeneic CAR T cell therapies in preclinical testing for various cancers...